Mesoblast (NASDAQ:MESO) Stock Rating Upgraded by Cantor Fitzgerald

Mesoblast (NASDAQ:MESO) was upgraded by equities research analysts at Cantor Fitzgerald to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Piper Sandler raised their price objective on Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, December 19th. Jefferies Financial Group downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Mesoblast Trading Up 3.2 %

Shares of MESO stock opened at $20.14 on Thursday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The company’s fifty day moving average price is $15.67 and its two-hundred day moving average price is $10.58. Mesoblast has a 12 month low of $1.75 and a 12 month high of $22.00.

Institutional Trading of Mesoblast

A number of institutional investors and hedge funds have recently modified their holdings of MESO. Strategic Financial Concepts LLC acquired a new stake in Mesoblast during the fourth quarter worth about $2,744,000. Marshall Wace LLP acquired a new stake in shares of Mesoblast during the 2nd quarter worth approximately $562,000. XY Capital Ltd bought a new stake in shares of Mesoblast in the 3rd quarter worth approximately $244,000. Jane Street Group LLC boosted its position in Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after purchasing an additional 26,959 shares during the period. Finally, Creative Planning bought a new position in Mesoblast during the 3rd quarter worth $147,000. 1.43% of the stock is owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.